A Phase 3 interventional study of Vasopressin; Methylprednisolone; Hydrocortisone in Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial, sponsored by Tiohundra AB. Recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Tiohundra AB · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing Arginine Vasopressin in Diabetes Insipidus — 12 open to participants now, 12 under way, 2 of them phase 3. Arginine Vasopressin · Diabetes Insipidus.
Among the 43 studies testing Arginine Vasopressin in Diabetes Insipidus, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2026, is one of 5 in phase 3, reaches primary completion later than 11 of the 11 other live ones, and was the 33rd registered.
191 studies on the registry are indexed under Diabetes Insipidus; 35 are open to participants now.
Browse Diabetes Insipidus studies →12 of the 43 studies testing Arginine Vasopressin in Diabetes Insipidus are open now, in 5 countries. Recruiting first, the newest first:
University of Electronic Science and Technology of China · Sites in China
Ages 18–30 · Healthy volunteers
The Cleveland Clinic · Sites in United States
Ages 18+
Jason Sperry · Sites in United States
Ages 18–90
University of Electronic Science and Technology of China · Sites in China
Ages 18–40 · Healthy volunteers
University of Electronic Science and Technology of China · Sites in China
Ages 18–40 · Healthy volunteers
By country, each count listing its studies:
Arginine Vasopressin: first FDA approval 2020 (VASOPRESSIN). What it is approved for, and how studies give it, is on its page →
Of the 30 Diabetes Insipidus studies recruiting now, 16 (53%) set no upper age limit and 11 (37%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 9 · Phase 4 8
First in 2000; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 784 is above the median of 77 across 118 interventional studies indexed under Diabetes Insipidus.
Median enrollment 105 across the 43 interventional studies. Of the 25 that completed or were terminated, 7 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 43 have an industry lead sponsor. The 10 most frequent:
Tiohundra AB is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Tiohundra AB has 1 study filed under Diabetes Insipidus — fewer than ten, so there is no comparison to draw.
5 of the studies testing Arginine Vasopressin in Diabetes Insipidus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04053478Samuel Lunenfeld Research Institute, Mount Sinai HospitalEffects of Ephedrine, Phenylephrine, Norepinephrine and Vasopressin on Contractility of Human Myometrium and Umbilical Vessels: An In-vitro Study | 2026-12 |
| NCT07838493University of Electronic Science and Technology of ChinaOromucosal Oxytocin and Vasopressin Modulation of Emotional Face Attention | 2026-12-18 |
| NCT03446456University of Maryland, BaltimoreVasopressin and Pain Perception in the Brain | 2026-12-31 |
| NCT05958342Jason SperryCAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial | 2027-03 |
| NCT06709573The Cleveland ClinicEarly Versus Late Adjunctive Vasopressin in Septic Shock | 2027-05-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 43 studies testing Arginine Vasopressin in Diabetes Insipidus, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an investigator initiated randomized, placebo controlled, open label, superiority, multi-centre clinical trial. The estimated study project period runs over 3-4 years, after now completed pilot phase. Based on preliminary assumptions, to confirm or reject an increase in survival from 16% to 24%, about 784 patients will be randomized in the study. In hospital cardiac arrest patients meeting criteria(s) for adrenaline administration according to current ERC guidelines, men > 18 years and women > 50, are eligible for randomization in the study.
Patients with do not resuscitate (DNR) decision will be excluded. Patients will be randomized to, in addition to adrenaline, either treatment with vasopressin and steroids (intervention) or standard care (control) Primary outcome is survival at 30 days.
An initial VAST-A pilot study with a previous protocol was conducted 2022-2024 to test feasibility and safety. The pilot results and experiences led to this VAST-A main trial with a revised protocol.
The criteria were revised on the registry on Nov 12, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adrenaline, vasopressin and steroids arm (intervention) 1. At randomization 1 ml of vasopressin 20 IU/ml will be administered as soon as possible after adrenaline during the five first cycles of drug administration during CPR. 1 ml metylprednisolone sodium succinate 40 mg/ml will be administered only during the first cycle of drug administration during CPR 2. In the ICU Hydrocortisone 3 mg/ml At 4 hours post ROSC, and then once daily, surviving patients will receive an infusion of 100 ml (300 mg hydrocortisone/ d) for ≤ 5 days.
Drug: Vasopressin; Methylprednisolone; Hydrocortisone
Standard care in cardiac arrest
Drug pages: Arginine VasopressinStudies of Arginine VasopressinArginine Vasopressin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MethylprednisoloneStudies of MethylprednisoloneMethylprednisolone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · HydrocortisoneStudies of HydrocortisoneHydrocortisone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Vasopressin, the vasoconstrictive hypophysal hormone, alone has not shown increased survival when compared to adrenaline. However, animal data have shown increased diastolic pressure, cerebral perfusion pressure and cerebral oxygenation in cardiac arrest treatment with vasopressin, and have when compared to adrenaline been associated with better cerebral blood flow. Corticosteroids are currently used in septic shock treatment as a means to reduce time to shock reversal and thereby potentially improving mortality. Steroids have therefore also been suggested for cardiac arrest treatment. The potential role in resuscitation includes the catecholaminerg potentiation, vasoconstriction and protection from reperfusion injury.
Survival at 30 days
Survival at 30 days
Time frame: Survival at 30 days
Plan to share: No
Started Oct 2026 (actual). Primary completion is estimated for Jan 2029, 27 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Nov 2021 → Oct 2026, primary completion Jan 2027 → Jan 2029 and completion Apr 2027 → Jun 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Arginine Vasopressin · Methylprednisolone · Hydrocortisone